Sign in Create account

Brooks Laboratories Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: BROOKS BSE: 533543
₹55.80
▼ -0.71 (-1.26%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
71/100
Strong
Valuation
47/100
Fairly Valued
Momentum
12/100
Bearish

QVM read Quality business Quality Strong, Valuation Fairly Valued, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹164 Cr
PE (TTM)
36.0
Industry median 36.1 (152 companies)
Price to Book
1.3
PEG (TTM)
-1.3
Institutions holding %
10.38%
FII + DII, latest filed period
Piotroski Score
6
Relative return vs Nifty50, qtr %
-6.7
Relative return vs Sector, qtr %
-22.8
Free Cash Flow
₹6 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-46.67%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
5.56%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-7.71%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-46.47%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-10.00%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.72
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.06
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
7.18
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
6.18%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
7.08%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
6.39%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
16.59%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
5.26%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
20.04%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 6)
  • Yes Debt to equity is below 0.5 (0.06)
  • Yes Return on equity is 15% or more (20.0%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 4 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.3%
Low 55.0200 · High 57.6100
1W return
-8.5%
Low 55.0200 · High 61.3500
1M return
-16.1%
Low 55.0200 · High 70.8000
52W return
-57.7%
Low 36.3000 · High 138.3400
Lifetime High ₹194.9700 (Jan. 6, 2025)
Lifetime Low ₹12.6500 (Dec. 30, 2011)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
57.3
10D
58.7
20D
60.4
50D
62.3
100D
63.8
200D
65.8

Delivery and volume

Day avg. delivery
73.9%
Week avg. delivery
71.8%
Month avg. delivery
67.2%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

56.14
Pivot
First resistance57.27
Second resistance58.73
Third resistance59.86
First support54.68
Second support53.55
Third support52.09
Day RSI34.6
Day MFI38.8
Day MACD-1.82
Day MACD signal-1.12

Beta

1M1.85
3M1.30
1Y1.51
3Y1.09

Price change analysis

↓ -16.1%
Over 1 Month
LowHigh
55.0270.80
↓ -22.8%
Over 3 Months
LowHigh
55.0279.69
↑ 25.3%
Over 6 Months
LowHigh
44.5679.70
↓ -57.7%
Over 1 Year
LowHigh
36.30138.34
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 36.0 (own history: 18.8–245.9)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹23 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹0.4800

Ranks #127 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter52.62%
  • Mutual funds9.90%
  • Other DII0.48%
  • Public37.00%

Largest holders

NameCategoryShares %Shares
Atul RanchalPromoter19.2400%5668060
Rajesh MahajanPromoter17.3600%5114151
Quant Mutual Fund - Quant Business Cycle FundPublic9.9000%2916111
Erwin MahajanPromoter4.1000%1206490
Rajni RanchalPromoter2.9200%861360

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 52.62% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 0.17% to 0.00% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 9.90% in Jun 2026 qtr

All shareholding details →

Insider trading, SAST & pledges

All 44 insider trades, 21 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
17 Nov 2024 Atul Ranchal Promoter Sell 0 ₹0
17 Nov 2024 Saras Gupta Promoter group Sell 0 ₹0
17 Nov 2024 Atul Ranchal Promoter Sell 0 ₹0
17 Nov 2024 Aryan Mahajan Promoter group Sell 0 ₹0
31 Aug 2023 Mr. Aryan Mahajan Promoter group Buy 0 ₹0
31 Aug 2023 Mr. Savvy Ranchal Promoter group Buy 0 ₹0
31 Aug 2023 Erwin Mahajan Promoter group Buy 0 ₹0
31 Aug 2023 Davinder Kumari Promoter group Buy 0 ₹0
31 Aug 2023 Selina Ranchal Promoter group Buy 0 ₹0
18 Feb 2021 Erwin Mahajan Promoter group Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 331 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
8 May 2026 RAMESH THAKURDAS JAISINGHANI Bulk Sell 170,803 50.5500 NSE
14 Nov 2024 ONE UP FINANCIAL CONSULTANTS PVT LTD Bulk Buy 400,000 136.4000 NSE
14 Nov 2024 ATUL RANCHAL Bulk Sell 395,011 136.4000 NSE
14 Nov 2024 ATUL RANCHAL Bulk Sell 200,000 137.4000 BSE
14 Nov 2024 RR FAMILY TRUST Bulk Buy 218,300 137.4000 BSE
14 Nov 2024 ARYAN MAHAJAN Bulk Sell 480,000 137.4000 BSE
16 May 2024 SARAVANA GLOBAL HOLDINGS LIMITED Bulk Sell 138,398 92.1200 NSE
21 Apr 2022 MUKUL MAHESHWARI (HUF) Bulk Buy 131,656 104.6700 NSE
21 Apr 2022 MUKUL MAHESHWARI (HUF) Bulk Sell 38,423 104.8300 NSE
3 Mar 2022 GUTTIKONDA VARA LAKSHMI Bulk Sell 160,000 89.2500 NSE

All bulk and block deals →

Corporate Actions

Full history (15 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
12 Sep 2024OTHERAnnual General Meeting
14 Sep 2023OTHERAnnual General Meeting
28 Jul 2023RIGHTSRights 1:16 @ Premium Rs 65/-
22 Sep 2022OTHERAnnual General Meeting
21 Sep 2021OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
13 Aug 2026 Financial Results Yes
29 May 2026 Financial Results Yes
6 Feb 2026 Financial Results Yes
14 Nov 2025 Financial Results Yes
13 Aug 2025 Financial Results Yes

Corporate Announcements

All 467 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
22 Sep 2026 Trading Window Brooks Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
16 Sep 2026 Company Update Brooks Laboratories Ltd - 533543 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
16 Sep 2026 Company Update Brooks Laboratories Ltd - 533543 - Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Sep 2026 Resignation Brooks Laboratories Limited has informed the Exchange regarding Resignation of Ms Krutika Rane as Company Secretary and Compliance Officer of the Company w.e.f. October 09, 2026.
16 Sep 2026 Resignation of Director/KMP/SMP Brooks Laboratories Limited has informed the Exchange about Resignation of Director/KMP/SMP
16 Sep 2026 Copy of Newspaper Publication Newspaper Publication regarding re-lodgement of transfer deed.
4 Sep 2026 AGM/EGM Brooks Laboratories Ltd - 533543 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
4 Sep 2026 Shareholders meeting Brooks Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 03, 2026. Further, the company has informed the Exchange regarding voting results.
3 Sep 2026 Shareholders meeting Brooks Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 03, 2026
22 Aug 2026 Copy of Newspaper Publication Please find enclosed herewith Addendum to the Notice of 24th Annual General Meeting.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.06)
  • Healthy liquidity (Current Ratio 1.72)

Weaknesses

  • Declining revenue YoY (-10.0%)
  • Declining profit YoY (-46.5%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (36.0) -- priced for continued strong execution
  • Down 57.7% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Brooks Laboratories Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.